Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain.
J Clin Hypertens (Greenwich)
; 22(8): 1379-1388, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-671828
ABSTRACT
The use of some anti-hypertensive drugs in the current COVID-19 pandemic has become controversial. This study investigated possible relationships between anti-hypertensive medications use and COVID-19 infection risk in the ambulatory hypertensive population. This is a population-based retrospective cohort study involving 34 936 hypertensive adults >50 years in Tarragona (Southern Catalonia, Spain) who were retrospectively followed through pandemic period (from 01/03/2020 to 30/04/2020). Two data sets including demographic/clinical characteristics (comorbidities and cardiovascular medications use) and laboratory PCR codes for COVID-19 were linked to construct an anonymized research database. Cox regression was used to calculate multivariable hazard ratios (HRs) and estimate the risk of suffering COVID-19 infection. Across study period, 205 PCR-confirmed COVID-19 cases were observed, which means an overall incidence of 586.8 cases per 100 000 persons-period. In multivariable analyses, only age (HR 1.03; 95% CI 1.02-1.05; P < .001) and nursing home residence (HR 19.60; 95% CI 13.80-27.84; P < .001) appeared significantly associated with increased risk of COVID-19. Considering anti-hypertensive drugs, receiving diuretics (HR 1.22; 95% CI 0.90-1.67; P = .205), calcium channel blockers (HR 1.29; 95%CI 0.91-1.82; P = .148), beta-blockers (HR 0.97; 95% CI 0.68-1.37; P = .844), and angiotensin-converting enzyme inhibitors (HR 0.83; 95% CI 0.61-1.13; P = .238) did not significantly alter the risk of PCR-confirmed COVID-19, whereas receiving angiotensin II receptor blockers was associated with an almost statistically significant reduction risk (HR 0.67; 95% CI 0.44-1.01; P = .054). In conclusion, our data support that receiving renin-angiotensin-aldosterone system inhibitors does not predispose for suffering COVID-19 infection in ambulatory hypertensive people. Conversely, receiving angiotensin II receptor blockers could be related with a reduced risk.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Renin-Angiotensin System
/
SARS-CoV-2
/
COVID-19
/
Hypertension
/
Antihypertensive Agents
Type of study:
Cohort study
/
Diagnostic study
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
English
Journal:
J Clin Hypertens (Greenwich)
Journal subject:
Vascular Diseases
Year:
2020
Document Type:
Article
Affiliation country:
Jch.13948
Similar
MEDLINE
...
LILACS
LIS